Literature DB >> 19072540

Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides.

William J Moore1, Jeffrey C Kern, Ramesh Bhat, Thomas J Commons, Shoichi Fukayama, Igor Goljer, Girija Krishnamurthy, Ronald L Magolda, Lisa Nogle, Keith Pitts, Barb Stauffer, Eugene J Trybulski, Gregory S Welmaker, Matthew Wilson, Peter V N Bodine.   

Abstract

The diphenylsulfonyl sulfonamide scaffold represented by 1 (WAY-316606) are small molecule inhibitors of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. Modulators of the Wnt pathway have been proposed as anabolic agents for the treatment of osteoporosis or other bone-related disorders. Details of the structure-activity relationships and biological activity from the first structural class of this scaffold will be discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19072540     DOI: 10.1021/jm801144h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

Review 1.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

Review 2.  Targeting Wnt pathways in disease.

Authors:  Zachary F Zimmerman; Randall T Moon; Andy J Chien
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

3.  Wnt signaling in bone formation and its therapeutic potential for bone diseases.

Authors:  Jeong Hwan Kim; Xing Liu; Jinhua Wang; Xiang Chen; Hongyu Zhang; Stephanie H Kim; Jing Cui; Ruidong Li; Wenwen Zhang; Yuhan Kong; Jiye Zhang; Wei Shui; Joseph Lamplot; Mary Rose Rogers; Chen Zhao; Ning Wang; Prashant Rajan; Justin Tomal; Joseph Statz; Ningning Wu; Hue H Luu; Rex C Haydon; Tong-Chuan He
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-02       Impact factor: 5.346

Review 4.  The role of small molecules in musculoskeletal regeneration.

Authors:  Kevin W-H Lo; Keshia M Ashe; Ho Man Kan; Cato T Laurencin
Journal:  Regen Med       Date:  2012-07       Impact factor: 3.806

Review 5.  Sclerosing bone dysplasias: leads toward novel osteoporosis treatments.

Authors:  Igor Fijalkowski; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

6.  Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.

Authors:  C A Simpson; D Foer; G S Lee; J Bihuniak; B Sun; R Sullivan; J Belsky; K L Insogna
Journal:  Osteoporos Int       Date:  2014-06-14       Impact factor: 4.507

7.  LRP5 and bone mass regulation: Where are we now?

Authors:  Mark L Johnson
Journal:  Bonekey Rep       Date:  2012-01-10

8.  Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy.

Authors:  Kristen R Georgiou; Susanta K Hui; Cory J Xian
Journal:  Am J Stem Cells       Date:  2012-11-30

Review 9.  Wnt signaling during fracture repair.

Authors:  Frank J Secreto; Luke H Hoeppner; Jennifer J Westendorf
Journal:  Curr Osteoporos Rep       Date:  2009-07       Impact factor: 5.096

10.  How genomics has informed our understanding of the pathogenesis of osteoporosis.

Authors:  Mark L Johnson; Nuria Lara; Mohamed A Kamel
Journal:  Genome Med       Date:  2009-09-07       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.